Literature DB >> 197600

Adenine and adenosine are toxic to human lymphoblast mutants defective in purine salvage enzymes.

M S Hershfield, F F Snyder, J E Seegmiller.   

Abstract

Mutants deficient in adenosine kinase or adenine phosphoribosyltransferase activities were selected from the WI-L2 line of human lymphoblasts. The adenosine kinase-deficient mutant was still as sensitive as its parent to growth inhibition caused by adenosine deaminase was inhibited. Similarly, the adenine phosphoribosyltransferase mutant remained sensitive to growth inhibition caused by adenine. Thus, the toxicity of adenine and adenosine to human lymphoblasts is not mediated by nucleotides to which they may be converted.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 197600     DOI: 10.1126/science.197600

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  24 in total

1.  Deficiency of AMP deaminase in erythrocytes.

Authors:  N Ogasawara; H Goto; Y Yamada; I Nishigaki; T Itoh; I Hasegawa; K S Park
Journal:  Hum Genet       Date:  1987-01       Impact factor: 4.132

Review 2.  Combined immunodeficiency and inborn errors of purine metabolism.

Authors:  H J Meuwissen; B Pollara
Journal:  Blut       Date:  1978-10-13

3.  Interstitial deletion for a region in the long arm of chromosome 16.

Authors:  C C Lin; R B Lowry; F F Snyder
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

4.  Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  M S Hershfield; J Kurtzberg; E Harden; J O Moore; J Whang-Peng; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

Review 5.  Adenosine deaminase inhibitors: their role in chemotherapy and immunosuppression.

Authors:  R I Glazer
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients.

Authors:  M S Hershfield; N M Kredich; D R Ownby; H Ownby; R Buckley
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

7.  Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation.

Authors:  M S Hershfield; N M Kredich
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

8.  Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.

Authors:  D A Carson; D B Wasson; J Kaye; B Ullman; D W Martin; R K Robins; J A Montgomery
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

9.  In vitro of adenosine on lymphocytes and erythrocytes from horses with combined immunodeficiency.

Authors:  N S Magnuson; L E Perryman
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

10.  Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.

Authors:  A S Bagnara; M S Hershfield
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.